Uso de omalizumab en cinco pacientes con síndrome de sobreposición asma-EPOC (SOAE) en un Hospital Universitario de Puebla: Un estudio observacional

diagnóstico (SOAE) Material métodos: 5 pacientes diagnóstico síndrome aplicación mg ABSTRACT. Introduction: The binomial term overlap asthma/COPD is a subset of patients with persistence and airflow limitation that presents clinical features of both asthma and COPD. Initial studies have shown that omalizumab may be useful in patients with ACOS, it has been shown to improve symptoms, reduce exacerbations and hospitalization, as well as improve lung function parameters and reduced steroid requirement in these patients. Objective: To describe the effect of omalizumab in 5 patients with a diagnosis of overlying asthma/COPD syndrome (OAC) and administration of omalizumab. We describe the experience of our center and the benefits that the treatment has given to our patients. Material and methods: We present 5 cases of patients with a diagnosis of overlap asthma/COPD syndrome after application of omalizumab (300 mg SC each month) significantly improved their symptoms in ACT (asthma control test) and respiratory function tests, mainly in spirometry. This 5 patients gave their consent to present cases. Results: The 5 patients with OAC received Omalizumab have experienced improvement of symptoms in ACT (asthma control test) and improvement of 10 to 20 and 25 points. Omalizumab was well tolerated without complications. 100% of patients showed improvement in symptoms (ACT), higher percentage are women as described in the literature, patients tolerated the treatment without presenting major adverse effects. Conclusion: The cases described offer initial evidence of our medical practice on the benefits of omalizumab in patients with clinically improving overlying asthma/COPD syndrome. Omalizumab demonstrates good tolerance without presenting adverse effects. These benefits have allowed the patient a better quality of life and radically reduce their morbidity. words: